December 10, 2012
Johnson & Johnson's (NYSE: JNJ ) drug Zytiga was just approved in a pre-chemotherapy indication for late-stage metastatic castration-resistant prostate cancer. This came as no surprise to investors; it received approval in Europe recently for a first-line therapy as well. In the following video, Motley Fool health-care analyst David Williamson talks about why this wasn't a big needle-mover for Johnson & Johnson share prices, but he also tells us that it was a critical step forward not only for J&J, which wants to see Zytiga hit the $1 billion mark, but also for Dendreon (NASDAQ: DNDN ) , which is working on some tandem treatment trials with Zytiga and its pre-chemo immunotherapy drug Provenge, that could prove to be huge share price drivers if successful.
Dendreon's run over the past four years had sub-$5 share prices skyrocketing to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseated from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand-new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.